Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPEED: Early Aggressive Therapy in PsA
NCT03739853Phase 4Completed
- Sponsor
- University of Oxford
- Start
- May 2019
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of adalimumab in psoriatic arthritis (PsA), sponsored by University of Oxford. Started May 2019; status: completed.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03739853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739853.